Changes in US stocks | New antiemetic drug Nereus received FDA approval, Wanda Biopharmaceuticals (VNDA.US) rose more than 32%

The Zhitong Finance App learned that on Wednesday, the stock price of Wanda Biopharmaceuticals (VNDA.US) rose. As of press release, the stock had risen more than 32% to $9.33. According to the news, the company said that its new drug, Nereus, has been approved by the US Food and Drug Administration (FDA), and that the drug can be used to prevent exercise-induced vomiting.

According to the company, the FDA's approval decision was based on the results of three clinical studies. The relevant test compared the medication group with the placebo group to assess the occurrence of vomiting. The data showed that Nereus achieved a “significant reduction” in reducing vomiting incidents, while showing “good safety characteristics” in short-term and acute use scenarios.

Vanda said it plans to officially launch Nereus within the next few months. The market generally believes that the approval of the drug is expected to bring new commercial growth points to the company and further enrich its product portfolio in the field of central nervous system and related indications.